Stada and Gedeon Richter have once again withdrawn their jointly-developed proposed pegfilgrastim biosimilar from evaluation at the European Medicines Agency (EMA) after questions were raised by the agency’s committee for human medicinal products (CHMP) over the risk-benefit assessment for the proposed Neulasta rival.
Richter and Stada initially withdrew a marketing authorization application for the biosimilar in December 2016 after data provided were insufficient...






